Video

Educated Patient® Leukemia and Lymphoma Summit: October 27, 2020

Author(s):

CURE Media Group

View the entire CURE® Educated Patient® Leukemia & Lymphoma Summit. A virtual event seeking to educate, inform and challenge the thinking of patients with leukemia and lymphoma.

View the entire CURE® Educated Patient® Leukemia & Lymphoma Summit. A virtual event seeking to educate, inform and challenge the thinking of patients with leukemia and lymphoma.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of two doctors and text.
Image of thumbnail.
Image of doctor.
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
Image of woman.
Image of Dr. Evens.
Image of carly.
Image of kelly.
Image of doctor.
Image of Dr. Kelly
Related Content
Image of two doctors and text.
June 12th 2025

What Patients With Genitourinary Cancers Need to Know After ASCO 2025

Ryan Scott
Dr. Joshua K. Sabari and Dr. Daniel V. Araujo provide expert insights into genitourinary cancer updates from ASCO 2025.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Image of hand.
June 10th 2025

Oncology Nurse Amanda Snyder Turns Personal Experience Into Advocacy

Jeanine Pronio
Amanda Snyder, a cancer survivor, became an oncology nurse to provide support she once lacked, now leading innovative therapies for patients.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
The ADC zilovertamab vedotin plus Rituxan and chemo showed an ORR of 56.3% in relapsed/refractory DLBCL: © stock.adobe.com.
June 9th 2025

Zilovertamab Vedotin Plus Chemo Combo Shows Responses in R/R DLBCL

Silas Inman
The antibody-drug conjugate zilovertamab vedotin plus Rituxan and chemotherapy showed an objective response rate of 56.3% in relapsed/refractory DLBCL.
The first patient has been dosed in the phase 3 TERZO trial of Copiktra for R/R nodal T-follicular helper cell lymphoma: © stock.adobe.com.
June 9th 2025

TERZO Trial Doses First Patient With Copiktra in Rare T-Cell Lymphoma

Spencer Feldman
The first patient has been dosed in the phase 3 TERZO trial of Copiktra for relapsed or refractory nodal T-follicular helper cell lymphoma.